[1] https://www.npr.org/sections/health-shots/2018/09/01/6416158...
[2] https://nymag.com/intelligencer/2019/07/another-person-has-d...
As to why people try to ration more expensive insulin is I suspect the “donut hole.” The young man in the first article aged out of his parent’s insurance, which was probably paying for his second-generation insulin. He probably had no idea what other options were available, or was concerned the first generation insulin was less safe.
A lot of people have limited executive functioning and our society isn’t good about helping them access the options available to them. A close family member of mine had a heart attack and was saddled with a $50,000 hospital bill. He had been eligible for Medicaid for years, but just never signed up.
The net price (what the manufacturer actually gets for Humalog) has dropped 16% since 2015. In 2019 the list price is $275 but the net price is $60.
https://1.bp.blogspot.com/-VfnPjfmmwUY/XzFtgfU87XI/AAAAAAAAq...
https://www.businessinsider.com/insulin-price-increased-last...
Note that those markup figures are based on production cost, excluding capital investment. Lilly is profitable, but not any more profitable than Google or Facebook or Apple.
Making critical products less profitable than less critical ones is often contrary to “the interests of the people.” It drives investment from stuff like new pharmaceuticals to stuff like dating apps.
Insulin is actually a perfect example of that. The first generation insulins now are relatively cheap. The “insulin” we’re talking about here are second-generation insulin analogs, which are easier to administer and help better control blood sugar levels. We are at the tail end of the patents on those and we are already starting to see generic insulin analogs being made at Wal-Mart.
You have to think about the system in terms of how humans work and their motivations. Brilliant people who can make new, better insulin aren’t born any more altruistic than the people whose talents are better suited to coming up with new advertising algorithms. They want to make a bunch of money from their work. If you make it so that smart people can make more money doing an ad-tech startup rather than a bio-tech startup, that’s what they’ll do.